Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
713 (USA) · Dr. Kowalski
consented 2012-09-19
AEs
2
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-10-30 (study day 42.0); relationship: PROBABLE
mild
assessed
Mild APPLICATION SITE DERMATITIS — outcome: RECOVERED/RESOLVED; onset 2012-10-30 (study day 42.0); relationship: PROBABLE
Data queries
No data queries.